MX2024015832A - Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedad relacionada con receptor de androgenos al usar el mismo - Google Patents
Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedad relacionada con receptor de androgenos al usar el mismoInfo
- Publication number
- MX2024015832A MX2024015832A MX2024015832A MX2024015832A MX2024015832A MX 2024015832 A MX2024015832 A MX 2024015832A MX 2024015832 A MX2024015832 A MX 2024015832A MX 2024015832 A MX2024015832 A MX 2024015832A MX 2024015832 A MX2024015832 A MX 2024015832A
- Authority
- MX
- Mexico
- Prior art keywords
- bifunctional compound
- sub
- androgen receptor
- pharmaceutical composition
- related disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357054P | 2022-06-30 | 2022-06-30 | |
| PCT/CN2023/103568 WO2024002205A1 (en) | 2022-06-30 | 2023-06-29 | Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024015832A true MX2024015832A (es) | 2025-04-02 |
Family
ID=89383152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015832A MX2024015832A (es) | 2022-06-30 | 2024-12-17 | Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedad relacionada con receptor de androgenos al usar el mismo |
| MX2024015833A MX2024015833A (es) | 2022-06-30 | 2024-12-17 | Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedades relacionadas con receptor de androgenos al usar el mismo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024015833A MX2024015833A (es) | 2022-06-30 | 2024-12-17 | Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedades relacionadas con receptor de androgenos al usar el mismo |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20250197409A1 (https=) |
| EP (2) | EP4547667A1 (https=) |
| JP (2) | JP2025524557A (https=) |
| KR (2) | KR20250027728A (https=) |
| CN (2) | CN119487035A (https=) |
| AU (2) | AU2023300784A1 (https=) |
| CA (2) | CA3259653A1 (https=) |
| IL (1) | IL318001A (https=) |
| MX (2) | MX2024015832A (https=) |
| TW (2) | TWI893405B (https=) |
| WO (3) | WO2024002289A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118955474A (zh) * | 2024-07-29 | 2024-11-15 | 浙江爱索拓标记医药科技有限公司 | 一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3658548A1 (en) * | 2017-07-28 | 2020-06-03 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| IL302595A (en) * | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| WO2020211822A1 (zh) * | 2019-04-18 | 2020-10-22 | 成都海创药业有限公司 | 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途 |
| CN114829342A (zh) * | 2019-12-23 | 2022-07-29 | 上海济煜医药科技有限公司 | 一种蛋白降解剂化合物的制备方法和应用 |
| WO2021143816A1 (zh) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用 |
| WO2021231927A1 (en) * | 2020-05-14 | 2021-11-18 | The Regents Of The University Of Michigan | Androgen receptor protein degraders with a tricyclic cereblon ligand |
| WO2022011205A1 (en) * | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| KR20220014952A (ko) * | 2020-07-29 | 2022-02-08 | 한국화학연구원 | 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도 |
| CN114163444B (zh) * | 2020-09-11 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| JP2023547084A (ja) * | 2020-10-21 | 2023-11-09 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体タンパク質の標的分解のための化合物および方法 |
-
2023
- 2023-06-29 AU AU2023300784A patent/AU2023300784A1/en active Pending
- 2023-06-29 WO PCT/CN2023/104153 patent/WO2024002289A1/en not_active Ceased
- 2023-06-29 TW TW112124416A patent/TWI893405B/zh active
- 2023-06-29 US US18/879,351 patent/US20250197409A1/en active Pending
- 2023-06-29 US US18/216,566 patent/US20240018149A1/en not_active Abandoned
- 2023-06-29 KR KR1020257001668A patent/KR20250027728A/ko active Pending
- 2023-06-29 CN CN202380051072.6A patent/CN119487035A/zh active Pending
- 2023-06-29 IL IL318001A patent/IL318001A/en unknown
- 2023-06-29 AU AU2023296682A patent/AU2023296682A1/en active Pending
- 2023-06-29 TW TW112124415A patent/TWI893404B/zh active
- 2023-06-29 CN CN202380051052.9A patent/CN119487034A/zh active Pending
- 2023-06-29 JP JP2024577399A patent/JP2025524557A/ja active Pending
- 2023-06-29 WO PCT/CN2023/103568 patent/WO2024002205A1/en not_active Ceased
- 2023-06-29 KR KR1020257001667A patent/KR20250028370A/ko active Pending
- 2023-06-29 EP EP23828665.2A patent/EP4547667A1/en active Pending
- 2023-06-29 WO PCT/CN2023/103576 patent/WO2024002206A1/en not_active Ceased
- 2023-06-29 EP EP23828676.9A patent/EP4547668A1/en active Pending
- 2023-06-29 CA CA3259653A patent/CA3259653A1/en active Pending
- 2023-06-29 CA CA3259652A patent/CA3259652A1/en active Pending
- 2023-06-29 JP JP2024577397A patent/JP2025520909A/ja active Pending
-
2024
- 2024-06-14 US US18/744,538 patent/US20240336620A1/en active Pending
- 2024-12-17 MX MX2024015832A patent/MX2024015832A/es unknown
- 2024-12-17 MX MX2024015833A patent/MX2024015833A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119487035A (zh) | 2025-02-18 |
| JP2025524557A (ja) | 2025-07-30 |
| AU2023296682A1 (en) | 2025-01-02 |
| IL318001A (en) | 2025-02-01 |
| EP4547668A1 (en) | 2025-05-07 |
| MX2024015833A (es) | 2025-04-02 |
| TWI893404B (zh) | 2025-08-11 |
| US20240018149A1 (en) | 2024-01-18 |
| EP4547667A1 (en) | 2025-05-07 |
| KR20250028370A (ko) | 2025-02-28 |
| CA3259653A1 (en) | 2024-01-04 |
| TW202404976A (zh) | 2024-02-01 |
| US20240336620A1 (en) | 2024-10-10 |
| WO2024002205A1 (en) | 2024-01-04 |
| JP2025520909A (ja) | 2025-07-03 |
| WO2024002206A1 (en) | 2024-01-04 |
| TWI893405B (zh) | 2025-08-11 |
| US20250197409A1 (en) | 2025-06-19 |
| CN119487034A (zh) | 2025-02-18 |
| TW202408505A (zh) | 2024-03-01 |
| WO2024002289A1 (en) | 2024-01-04 |
| AU2023300784A1 (en) | 2025-01-02 |
| KR20250027728A (ko) | 2025-02-27 |
| CA3259652A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533398A5 (https=) | ||
| CN109790135B (zh) | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 | |
| JP2023500611A5 (https=) | ||
| JP2004529874A5 (https=) | ||
| MX2024015832A (es) | Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedad relacionada con receptor de androgenos al usar el mismo | |
| CA2394327A1 (en) | Substituted piperazine and piperidine calcium channel blockers | |
| RU96101139A (ru) | Новые производные эритромицина, способ их получения и применение в качестве лекарственных средств | |
| DE10178132T1 (de) | Antivirales Mittel | |
| RU97119064A (ru) | Применение альфа(il)-агонистов для лечения недержания мочи | |
| JP2007517007A5 (https=) | ||
| BRPI0924126A2 (pt) | composto heterocíclico bicíclico | |
| JP2003509349A5 (https=) | ||
| CN119143585A (zh) | 双酚衍生物和其作为雄激素受体活性调节剂的用途 | |
| JP2005514457A5 (https=) | ||
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| NL8204126A (nl) | Werkwijze voor het bereiden van een farmaceutisch preparaat met locaal-anesthetische werking dat een dialylamino-2',6'acetoxylidide en/of een farmaceutisch aanvaardbaar zout daarvan bevat, alsmede de onder toepassing van deze werkwijze verkregen gevormde farmaceutische preparaten en werkwijze voor het bereiden van dialkylamino-2',6'acetoxylididen en de farmaceutisch aanvaardbare zouten daarvan. | |
| AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| JP2005525364A5 (https=) | ||
| EP2139865B1 (en) | Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime | |
| RU2006130686A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| JP2009504712A5 (https=) | ||
| RU2008109911A (ru) | Способ применения соединений, ингибирующих калиевые каналы | |
| JP2000516257A5 (https=) | ||
| MXPA05005587A (es) | Composicion liquida concentrada de valdecoxib. | |
| RU2004111789A (ru) | Ретиноидные агонисты |